Kura Oncology (NASDAQ:KURA) has been given a $18.00 price objective by equities researchers at Oppenheimer in a research report issued to clients and investors on Monday. The firm currently has a “buy” rating on the stock. Oppenheimer’s price target suggests a potential upside of 29.96% from the company’s previous close.

A number of other brokerages also recently issued reports on KURA. ValuEngine downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Zacks Investment Research downgraded Kura Oncology from a “buy” rating to a “hold” rating in a research report on Friday, September 29th. Cann reaffirmed a “buy” rating and set a $17.50 price target on shares of Kura Oncology in a research report on Monday. BidaskClub downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. Finally, Citigroup upped their price target on Kura Oncology from $15.00 to $19.00 and gave the stock a “buy” rating in a research report on Thursday, November 9th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. Kura Oncology presently has a consensus rating of “Hold” and a consensus target price of $17.90.

Shares of Kura Oncology (KURA) opened at $13.85 on Monday. The company has a quick ratio of 13.48, a current ratio of 13.48 and a debt-to-equity ratio of 0.07. Kura Oncology has a twelve month low of $5.33 and a twelve month high of $17.50.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Tuesday, November 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). equities analysts anticipate that Kura Oncology will post -1.45 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KURA. Morgan Stanley increased its position in shares of Kura Oncology by 175.5% in the 1st quarter. Morgan Stanley now owns 430,428 shares of the company’s stock valued at $3,788,000 after acquiring an additional 274,166 shares during the period. Renaissance Technologies LLC increased its position in shares of Kura Oncology by 158.8% in the 1st quarter. Renaissance Technologies LLC now owns 79,200 shares of the company’s stock valued at $697,000 after acquiring an additional 48,600 shares during the period. Goldman Sachs Group Inc. acquired a new position in shares of Kura Oncology in the 1st quarter valued at $533,000. Schwab Charles Investment Management Inc. acquired a new position in shares of Kura Oncology in the 2nd quarter valued at $226,000. Finally, Rhumbline Advisers acquired a new position in shares of Kura Oncology in the 2nd quarter valued at $131,000. 64.26% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.watchlistnews.com/kura-oncology-kura-given-a-18-00-price-target-at-oppenheimer/1758918.html.

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.